Vasiľ Hricák
„Nothing is clearest over and about that what we found out yesterday , nothing is harder to foresee as that what we will find out tomorrow“(Charles Seward) Background: Antiplatelet therapy is inevitable in the frame of management of acute coronary syndromes (ACS) whether in conservative or interventional and surgical strategies of ACS. Present antiplatelet therapy with clopidogrel + aspirin distinctively contributed to improvement of the treatment for patients with ACS, but despite such treatment thrombotic events persist in earlier or later horizon. Aim: Briefly to approach and summarise essential knowledge on new antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome with or without elevation of ST segment in ECG scan (STEMI, NSTEMI and NAP - instable angina pectoris). Conclusion: New antiplatelet drugs are an important contribution in treatment of ACS. Prasugrel with exceptionally prompt onset of effect, and important effectiveness already in first days, has an optimal position in the frame of STEMI, unless contradictions are present. Prasugrel, due to its safety and dominant benefit in diabetics treated with PKI, has to be the drug of choice. Ticagrelor is, by its mechanism of effectiveness and results in treatment of patients with ACS, a breakthrough drug which belongs to everyday antiplatelet armamentarium in the frame of ACS. A distinct profit from treatment with ticagrelor versus other modern antiplatelet treatment is visible in patients with ACS at the age ≥ 75, weight ≤ 60 kg, creatinine clearance ≤ 60 ml/min, who are after TIA, or after ischemic stroke, are sensitive to thienopyridines, even patients already treated with clopidogrel, patients without knowledge of coronary anatomy. Prasugrel and also ticagrelor are administered together with aspirin if there are not absolute contraindications and as soon as possible in patients with ACS. In patients with ACS, if due to any reasons it is not possible to administer ticagrelor or prasugrel, clopidogrel is still indicated.